Prostate Cancer: A Journey Through Its History and Recent Developments

被引:2
作者
Mallah, Hamza
Diabasana, Zania
Soultani, Sina
Idoux-Gillet, Ysia
Massfelder, Thierry [1 ]
机构
[1] Ctr Rech Biomed Strasbourg, Regenerat NanoMed, Federat Med Translat Strasbourg FMTS, UMR S U1260 INSERM, F-67085 Strasbourg, France
关键词
prostate cancer; surgery; radiation therapy; hormone therapy; immunotherapy; resistance; personalized medicine; MITOXANTRONE PLUS PREDNISONE; HEDGEHOG SIGNALING PATHWAY; MULTICENTER PHASE-II; RADICAL PROSTATECTOMY; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; SYSTEMIC THERAPY; CELL-MIGRATION; DOUBLE-BLIND; CASTRATION;
D O I
10.3390/cancers17020194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer is one of the most common diseases among men worldwide and continues to pose a serious threat to health. This review shows the history and the new developments in the management of prostate cancer, with an emphasis on a range of therapeutic approaches, such as hormone therapy, radiation therapy, surgery, and innovative targeted therapeutics. The evolution of these treatments is examined in light of clinical outcomes, patient quality of life, and emerging resistance mechanisms, such as the recently shown vitamin D-based strategies. New developments that have the potential to increase survival rates and reduce side effects are also discussed, including PARP inhibitors (PARPis), immunotherapy, and tailored medication. Additionally, the use of biomarkers and sophisticated imaging methods in therapeutic decision-making is explored, with a focus on how these tools might improve patient care. The absolute necessity for a multidisciplinary approach for improving treatment strategies is becoming more and more apparent as our understanding of the biology of prostate cancer deepens. This approach ensures that patients receive customized medicines that fit their unique profiles. Future avenues of investigation will focus on resolving issues dealing with treatment efficacy and resistance to improve treatment results, ultimately leading to disease cure for prostate cancer patients.
引用
收藏
页数:27
相关论文
共 178 条
[1]   Cabazitaxel: A novel taxane for metastatic castration- resistant prostate cancer-current implications and future prospects [J].
Abidi, Afroz .
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2013, 4 (04) :230-237
[2]   Localized and Locally Advanced Prostate Cancer: Treatment Options [J].
Achard, Verane ;
Panje, Cedric Michael ;
Engeler, Daniel ;
Zilli, Thomas ;
Putora, Paul Martin .
ONCOLOGY, 2021, :413-421
[3]   Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics [J].
Adamaki, Maria ;
Zoumpourlis, Vassilios .
PHARMACOLOGY & THERAPEUTICS, 2021, 228
[4]  
Agarwal N, 2023, LANCET, V402, P291, DOI 10.1016/S0140-6736(23)01055-3
[5]   Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer [J].
Allouchery, Marion ;
Lombard, Thomas ;
Martin, Mickael ;
Rouby, Franck ;
Sassier, Marion ;
Bertin, Celia ;
Atzenhoffer, Marina ;
Miremont-Salame, Ghada ;
Perault-Pochat, Marie-Christine ;
Puyade, Mathieu .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[6]   Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study [J].
Antonarakis, Emmanuel S. ;
Piulats, Josep M. ;
Gross-Goupil, Marine ;
Goh, Jeffrey ;
Ojamaa, Kristiina ;
Hoimes, Christopher J. ;
Vaishampayan, Ulka ;
Berger, Ranaan ;
Sezer, Ahmet ;
Alanko, Tuomo ;
de Wit, Ronald ;
Li, Chunde ;
Omlin, Aurelius ;
Procopio, Giuseppe ;
Fukasawa, Satoshi ;
Tabata, Ken-ichi ;
Park, Se Hoon ;
Feyerabend, Susan ;
Drake, Charles G. ;
Wu, Haiyan ;
Qiu, Ping ;
Kim, Jeri ;
Poehlein, Christian ;
de Bono, Johann Sebastian .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[7]   Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer [J].
Araki, Shinako ;
Omori, Yohei ;
Lyn, Dominic ;
Singh, Rajendra K. ;
Meinbach, David M. ;
Sandman, Yekutiel ;
Lokeshwar, Vinata B. ;
Lokeshwar, Bal L. .
CANCER RESEARCH, 2007, 67 (14) :6854-6862
[8]   Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break? [J].
Attard, Gerhardt ;
Cooper, Colin S. ;
de Bono, Johann S. .
CANCER CELL, 2009, 16 (06) :458-462
[9]   TGF- Effects on Prostate Cancer Cell Migration and Invasion Require FosB [J].
Barrett, Cachetne S. X. ;
Millena, Ana C. ;
Khan, Shafiq A. .
PROSTATE, 2017, 77 (01) :72-81
[10]   Prostate-specificy-antigen testing for early diagnosis of prostate cancer. [J].
Barry, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (18) :1373-1377